Sfoglia per Rivista HAEMATOLOGICA
Idarubicin and Ara-C in the treatment of refractory and relapsed ALL
1991 Testi, Anna Maria; Annino, Luciana; Giona, Fiorina; R., Miniero; Meloni, Giovanna; M. L., Moleti; A., Tangorra; Mandelli, Franco
Identical, single center policy for unrelated cord blood transplant in young patients with high risk acute lymphoblastic leukemia: a long-term follow up
2003 Iori, Ap; Cerretti, R; De Felice, L; Screnci, M; Mengarelli, A; Roveda, A; Romano, A; Caniglia, M; Gentile, Giuseppe; Moleti, Ml; Giona, Fiorina; Agostani, F; Pasqua, I; Pinto, Mr; Teodonio, S; Ciriello, F; Testi, Anna Maria; Mandelli, Franco; Arcese, William
Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method.
2008 I., Iacobucci; A., Lonetti; D., Cilloni; F., Messa; A., Ferrari; R., Zuntini; S., Ferrari; E., Ottaviani; F., Arruga; S., Paolini; C., Papayannidis; P. P., Piccaluga; S., Soverini; G., Saglio; F., Pane; A., Baruzzi; Vignetti, Marco; G., Berton; A., Vitale; Chiaretti, Sabina; M., Müschen; Foa, Roberto; M., Baccarani; G., Martinelli
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease.
2013 Marinelli, Marilisa; Peragine, Nadia; Di Maio, V; Chiaretti, Sabina; De Propris, Ms; Raponi, Sara; Tavolaro, Simona; Mauro, Francesca Romana; DEL GIUDICE, Ilaria; Guarini, Anna; Foa, Roberto
Identification of monoclonal B-cell lymphocytosis (MBL) among sibling transplant donors for Chronic Lymphocytic Leukemia (CLL)
2009 DEL GIUDICE, Ilaria; Mauro, Francesca Romana; De Propris, M. S.; DELLA STARZA, Irene; Armiento, Daniele; Iori, A. P.; Torelli, Giovanni Fernando; Guarini, A.; Foà, R.
Identification of risk factors in atypical chronic myeloid leukemia
2006 M., Breccia; F., Biondo; R., Latagliata; I., Carmosino; Mandelli, Franco; Alimena, Giuliana
THE IELSG-32 TRIAL: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION VS HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
2015 Ferreri, Ajm; Cwynarski, K; Pulczynski, E; Ponzoni, M; Politi, Ls; Ambrosetti, A; Vitolo, U; Ilariucci, F; Balzarotti, M; Fabbri, A; Tucci, A; Pisani, F; Levis, A; Cabras, Mg; D'Arco, M; Zaccaria, A; Angrilli, F; Guarini, Anna; Imola, M; Martelli, Maurizio; Cervetti, J; Zaja, F; Pinto, A; Liberati, M; Morra, E; Cortellazzo, Sf; Bassan, R; Foppoli, M; Citterio, G; Sassone, M; Scarfo, L; Cavalli, F; Finke, J; Reni, M; Zucca, E; Illerhaus, G.
IGHV1-69/D3-16/J3 subset 6 is associate with indolent disease course of early stage CLL (RAI 0) independent of unmutated status.
2010 Forconi, F; Cencini, E; Rossi, D; Sozzi, E; Bomben, R; Marasca, R; Coscia, M; Massaia, M; Veronese, S; Tedeschi, A; Montillo, M; Fazzi, R; Petrini, M; Ciolli, S; Bosi, A; Dottori, R; Pirrotta, M; Caremani, A; Del Poeta, G; DEL GIUDICE, Ilaria; Santangelo, S; Laurenti, L; Efremov, D; Trentin, L; Bertoni, F; Gattei, V; Gaidano, G; Lauria, F.
IGHV1-69/D3-16/J3 subset 6 is associated with indolent disease course of early stage CLL (RAI 0), which is independent of unmutated IGH status.
2010 Forconi, F; Sozzi, E; Rossi, D; Cencini, E; Sicuranza, A; Marasca, R; Coscia, M; Massaia, M; Veronese, S; Tedeschi, A; Montillo, M; Fazzi, R; Petrini, M; Ciolli, S; Bosi, A; Dottori, R; Algeri, R; Pirrotta, Mt; Caremani, A; Bomben, R; Del Poeta, G; DEL GIUDICE, Ilaria; Santangelo, S; Laurenti, L; Efremov, D; Trentin, L; Bertoni, F; Gattei, V; Gaidano, G; Lauria, F.
IgVH mutations in patients with chronic lymphocytic leukemia.
2005 Foa, Roberto
IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study
1990 Meloni, Giovanna; Foa, Roberto; Tosti, S; Vignetti, Marco; Gavosto, F; Mandelli, Franco
IL28B polymorphisms influence stage of the liver fibrosis and spontaneousor interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.
2012 Di Marco, V; Bronte, F; Calvaruso, V; Capra, M; Borsellino, Z; Maggio, A; Renda, Mc; Pitrolo, L; Lo Pinto, Mc; Rizzo, M; Fiorenza, F; Gerardi, C; Grimaudo, S; Di Cristina, A; Levrero, Massimo; Craxi', A.
IMATINIB 400 MG IN LATE CHRONIC PHASE CML PATIENTS: LONG TERM EVALUATION OF RESPONSES AND SURVIVAL OF A PHASE II STUDY OF THE GIMEMA CML WP
2007 Palandri, F; Iacobucci, I; Castagnetti, F; Testoni, N; Amabile, M; Bassi, S; Soverini, S; Saglio, G; Pane, F; Breccia, M; Bassan, R; Martino, B; Merante, S; Giannoulia, P; Martinelli, G; Rosti, G; Baccarani, M
IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS IN EARLY CHRONIC PHASE: RESULTS OF AN OBSERVATIONAL, MULTICENTRIC PROSPECTIVE TRIAL OF THE GIMEMA CML WP
2007 Castagnetti, F; Iacobucci, I; Palandri, F; Marzocchi, G; Giannoulia, P; Amabile, M; Intermesoli, T; Breccia, M; Radaelli, F; Usala, E; Abruzzese, E; Pane, F; Saglio, G; Martinelli, G; Baccarani, M; Rosti, G
IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS: EARLY RESULTS OF AN OBSER- VATIONAL, MULTICENTRIC TRIAL OF THE GIMEMA CML WP
2006 Rosti, G; Castagnetti, F; Iacobucci, I; Testoni, N; Breccia, M; Palandri, F; Specchia, G; Martino, B; Luatti, S; Capucci, A; Poerio, A; Bassan, R; Pane, F; Saglio, G; Martinelli, G; Baccarani, M
IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS: RESULTS OF AN OBSERVATIONAL, MULTICENTRIC TRIAL OF THE GIMEMA CML WP
2006 Rosti, G; Castagnetti, F; Iacobucci, I; Testoni, N; Breccia, M; Specchia, G; Martino, B; Palandri, F; Poerio, A; Luatti, S; Capucci, A; Bassan, R; Martinelli, G; Saglio, G; Pane, F; Baccarani, M
IMATINIB 400 MG IN PHILADELPHIA POSITIVE LATE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. AN ANALYSIS OF THE DURATION OF COMPLETE CYTOGENETIC RESPONSE AND OF MAJOR MOLECULAR RESPONSE IN THE LONG-TERM
2007 Breccia, M; Palandri, F; Iacobucci, I; Martinelli, G; Amabile, M; Soverini, S; Castagnetti, F; Testoni, N; Luatti, S; Specchia, G; Abruzzese, E; Martino, B; Cilloni, D; Saglio, G; Pane, F; Russo, D; Alimena, G; Rosti, G; Baccarani, M
IMATINIB 600 MG ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA INDUCES DURABLE CYTOGENETIC RESPONSES IN THE LONG-TERM: THE GIMEMA CML WORKING PARTY EXPERIENCE AFTER A 7-YEAR FOLLOW-UP
2008 Palandri, F; Castagnetti, F; Testoni, N; Alimena, G; Rege-Cambrin, G; Breccia, M; Specchia, G; Bruno, M; Miglino, M; Levato, L; Saglio, G; Pane, F; Martinelli, G; Baccarani, M; Rosti, G
IMATINIB 600 MG IN ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA INDUCES DURABLE CYTOGENETIC RESPONSES IN THE LONG-TERM: THE GIMEMA CML WORKING PARTY EXPERIENCE AFTER A 7-YEAR FOLLOW-UP
2008 Palandri, F; Castagnetti, F; Testoni, N; Alimena, G; Breccia, M; Levato, F; Specchia, G; Martino, B; Rege-Cambrin, G; Miglino, M; Saglio, G; Pane, F; Martinelli, G; Baccarani, M; Rosti, G; on behalf of the GIMEMA Working Party on, Cml
IMATINIB 800 MG IN INTERMEDIATE SOKAL RISK CML PATIENTS IN EARLY CHRONIC PHASE: RESULTS OF A PHASE II TRIAL OF THE GIMEMA CML WP
2006 Castagnetti, F; Rosti, G; Amabile, M; Iacobucci, I; Testoni, N; Marzocchi, G; Breccia, M; Galieni, P; Stagno, F; Palandri, F; Iuliano, F; Abruzzese, E; Saglio, G; Martinelli, G; Pane, F; Baccarani, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Idarubicin and Ara-C in the treatment of refractory and relapsed ALL | 1991 | Testi, Anna Maria; Annino, Luciana; Giona, Fiorina; R., Miniero; Meloni, Giovanna; M. L., Moleti; A., Tangorra; Mandelli, Franco | |
| Identical, single center policy for unrelated cord blood transplant in young patients with high risk acute lymphoblastic leukemia: a long-term follow up | 2003 | Iori, Ap; Cerretti, R; De Felice, L; Screnci, M; Mengarelli, A; Roveda, A; Romano, A; Caniglia, M; Gentile, Giuseppe; Moleti, Ml; Giona, Fiorina; Agostani, F; Pasqua, I; Pinto, Mr; Teodonio, S; Ciriello, F; Testi, Anna Maria; Mandelli, Franco; Arcese, William | |
| Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. | 2008 | I., Iacobucci; A., Lonetti; D., Cilloni; F., Messa; A., Ferrari; R., Zuntini; S., Ferrari; E., Ottaviani; F., Arruga; S., Paolini; C., Papayannidis; P. P., Piccaluga; S., Soverini; G., Saglio; F., Pane; A., Baruzzi; Vignetti, Marco; G., Berton; A., Vitale; Chiaretti, Sabina; M., Müschen; Foa, Roberto; M., Baccarani; G., Martinelli | |
| Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. | 2013 | Marinelli, Marilisa; Peragine, Nadia; Di Maio, V; Chiaretti, Sabina; De Propris, Ms; Raponi, Sara; Tavolaro, Simona; Mauro, Francesca Romana; DEL GIUDICE, Ilaria; Guarini, Anna; Foa, Roberto | |
| Identification of monoclonal B-cell lymphocytosis (MBL) among sibling transplant donors for Chronic Lymphocytic Leukemia (CLL) | 2009 | DEL GIUDICE, Ilaria; Mauro, Francesca Romana; De Propris, M. S.; DELLA STARZA, Irene; Armiento, Daniele; Iori, A. P.; Torelli, Giovanni Fernando; Guarini, A.; Foà, R. | |
| Identification of risk factors in atypical chronic myeloid leukemia | 2006 | M., Breccia; F., Biondo; R., Latagliata; I., Carmosino; Mandelli, Franco; Alimena, Giuliana | |
| THE IELSG-32 TRIAL: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION VS HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA | 2015 | Ferreri, Ajm; Cwynarski, K; Pulczynski, E; Ponzoni, M; Politi, Ls; Ambrosetti, A; Vitolo, U; Ilariucci, F; Balzarotti, M; Fabbri, A; Tucci, A; Pisani, F; Levis, A; Cabras, Mg; D'Arco, M; Zaccaria, A; Angrilli, F; Guarini, Anna; Imola, M; Martelli, Maurizio; Cervetti, J; Zaja, F; Pinto, A; Liberati, M; Morra, E; Cortellazzo, Sf; Bassan, R; Foppoli, M; Citterio, G; Sassone, M; Scarfo, L; Cavalli, F; Finke, J; Reni, M; Zucca, E; Illerhaus, G. | |
| IGHV1-69/D3-16/J3 subset 6 is associate with indolent disease course of early stage CLL (RAI 0) independent of unmutated status. | 2010 | Forconi, F; Cencini, E; Rossi, D; Sozzi, E; Bomben, R; Marasca, R; Coscia, M; Massaia, M; Veronese, S; Tedeschi, A; Montillo, M; Fazzi, R; Petrini, M; Ciolli, S; Bosi, A; Dottori, R; Pirrotta, M; Caremani, A; Del Poeta, G; DEL GIUDICE, Ilaria; Santangelo, S; Laurenti, L; Efremov, D; Trentin, L; Bertoni, F; Gattei, V; Gaidano, G; Lauria, F. | |
| IGHV1-69/D3-16/J3 subset 6 is associated with indolent disease course of early stage CLL (RAI 0), which is independent of unmutated IGH status. | 2010 | Forconi, F; Sozzi, E; Rossi, D; Cencini, E; Sicuranza, A; Marasca, R; Coscia, M; Massaia, M; Veronese, S; Tedeschi, A; Montillo, M; Fazzi, R; Petrini, M; Ciolli, S; Bosi, A; Dottori, R; Algeri, R; Pirrotta, Mt; Caremani, A; Bomben, R; Del Poeta, G; DEL GIUDICE, Ilaria; Santangelo, S; Laurenti, L; Efremov, D; Trentin, L; Bertoni, F; Gattei, V; Gaidano, G; Lauria, F. | |
| IgVH mutations in patients with chronic lymphocytic leukemia. | 2005 | Foa, Roberto | |
| IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study | 1990 | Meloni, Giovanna; Foa, Roberto; Tosti, S; Vignetti, Marco; Gavosto, F; Mandelli, Franco | |
| IL28B polymorphisms influence stage of the liver fibrosis and spontaneousor interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. | 2012 | Di Marco, V; Bronte, F; Calvaruso, V; Capra, M; Borsellino, Z; Maggio, A; Renda, Mc; Pitrolo, L; Lo Pinto, Mc; Rizzo, M; Fiorenza, F; Gerardi, C; Grimaudo, S; Di Cristina, A; Levrero, Massimo; Craxi', A. | |
| IMATINIB 400 MG IN LATE CHRONIC PHASE CML PATIENTS: LONG TERM EVALUATION OF RESPONSES AND SURVIVAL OF A PHASE II STUDY OF THE GIMEMA CML WP | 2007 | Palandri, F; Iacobucci, I; Castagnetti, F; Testoni, N; Amabile, M; Bassi, S; Soverini, S; Saglio, G; Pane, F; Breccia, M; Bassan, R; Martino, B; Merante, S; Giannoulia, P; Martinelli, G; Rosti, G; Baccarani, M | |
| IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS IN EARLY CHRONIC PHASE: RESULTS OF AN OBSERVATIONAL, MULTICENTRIC PROSPECTIVE TRIAL OF THE GIMEMA CML WP | 2007 | Castagnetti, F; Iacobucci, I; Palandri, F; Marzocchi, G; Giannoulia, P; Amabile, M; Intermesoli, T; Breccia, M; Radaelli, F; Usala, E; Abruzzese, E; Pane, F; Saglio, G; Martinelli, G; Baccarani, M; Rosti, G | |
| IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS: EARLY RESULTS OF AN OBSER- VATIONAL, MULTICENTRIC TRIAL OF THE GIMEMA CML WP | 2006 | Rosti, G; Castagnetti, F; Iacobucci, I; Testoni, N; Breccia, M; Palandri, F; Specchia, G; Martino, B; Luatti, S; Capucci, A; Poerio, A; Bassan, R; Pane, F; Saglio, G; Martinelli, G; Baccarani, M | |
| IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS: RESULTS OF AN OBSERVATIONAL, MULTICENTRIC TRIAL OF THE GIMEMA CML WP | 2006 | Rosti, G; Castagnetti, F; Iacobucci, I; Testoni, N; Breccia, M; Specchia, G; Martino, B; Palandri, F; Poerio, A; Luatti, S; Capucci, A; Bassan, R; Martinelli, G; Saglio, G; Pane, F; Baccarani, M | |
| IMATINIB 400 MG IN PHILADELPHIA POSITIVE LATE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. AN ANALYSIS OF THE DURATION OF COMPLETE CYTOGENETIC RESPONSE AND OF MAJOR MOLECULAR RESPONSE IN THE LONG-TERM | 2007 | Breccia, M; Palandri, F; Iacobucci, I; Martinelli, G; Amabile, M; Soverini, S; Castagnetti, F; Testoni, N; Luatti, S; Specchia, G; Abruzzese, E; Martino, B; Cilloni, D; Saglio, G; Pane, F; Russo, D; Alimena, G; Rosti, G; Baccarani, M | |
| IMATINIB 600 MG ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA INDUCES DURABLE CYTOGENETIC RESPONSES IN THE LONG-TERM: THE GIMEMA CML WORKING PARTY EXPERIENCE AFTER A 7-YEAR FOLLOW-UP | 2008 | Palandri, F; Castagnetti, F; Testoni, N; Alimena, G; Rege-Cambrin, G; Breccia, M; Specchia, G; Bruno, M; Miglino, M; Levato, L; Saglio, G; Pane, F; Martinelli, G; Baccarani, M; Rosti, G | |
| IMATINIB 600 MG IN ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA INDUCES DURABLE CYTOGENETIC RESPONSES IN THE LONG-TERM: THE GIMEMA CML WORKING PARTY EXPERIENCE AFTER A 7-YEAR FOLLOW-UP | 2008 | Palandri, F; Castagnetti, F; Testoni, N; Alimena, G; Breccia, M; Levato, F; Specchia, G; Martino, B; Rege-Cambrin, G; Miglino, M; Saglio, G; Pane, F; Martinelli, G; Baccarani, M; Rosti, G; on behalf of the GIMEMA Working Party on, Cml | |
| IMATINIB 800 MG IN INTERMEDIATE SOKAL RISK CML PATIENTS IN EARLY CHRONIC PHASE: RESULTS OF A PHASE II TRIAL OF THE GIMEMA CML WP | 2006 | Castagnetti, F; Rosti, G; Amabile, M; Iacobucci, I; Testoni, N; Marzocchi, G; Breccia, M; Galieni, P; Stagno, F; Palandri, F; Iuliano, F; Abruzzese, E; Saglio, G; Martinelli, G; Pane, F; Baccarani, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile